Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma
JCO Precision Oncology · 2025-06 · (9)
DOI: 10.1200/po-24-00879 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-06. Verfasst von Vadim S Koshkin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Gene Amplification, Urologic Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The aim of this study was to assess the prevalence of human epidermal growth factor receptor 2 (HER2) protein expression and ERBB2 gene amplification in a large cohort of tumor samples from patients with advanced urothelial carcinoma (UC). MATERIALS AND METHODS Testing was performed on formalin-fixed, paraffin-embedded tissue from commercially sourced primary advanced or metastatic UC using an anti-HER2/neu (4B5) rabbit monoclonal antibody immunohistochemistry (IHC) assay (detects HER2 protein) and HER2 dual in situ hybridization (DISH) DNA probe cocktail assay (detects ERBB2 gene and the centromere of its residing chromosome 17). The HER2 clinical status was classified as HER2-zero (IHC 0), HER2-low (IHC 1+ or IHC 2+/DISH nonamplified), or HER2-positive (IHC 2+/DISH amplified or IHC 3+). RESULTS Of the 2,024 UC samples, HER2 protein expression was IHC 0 for 962 (47.5%), IHC 1+ for 297 (14.7%), IHC 2+ for 498 (24.6%), and IHC 3+ for 267 (13.2%). The percentage of HER2-expressing tumors (IHC 1+, 2+, and 3+) was similar between primary (52.2%, 1,028/1,968) and metastatic UC samples (60.7%, 34/56; P = .26). The ERBB2 gene was amplified in 235 cases (11.6%), including 2.7%/3.7%/9.6%/56.2% scored as IHC 0/1+/2+/3+, respectively. Overall, HER2 clinical status was HER2-zero for 962 UC tissue samples (47.5%; 95% CI, 45.4 to 49.7), HER2-low for 747 (36.9%; 95% CI, 34.8 to 39.0), and HER2-positive for 315 (15.6%; 95% CI, 14.0 to 17.2). CONCLUSION We observed that more than 50% of 2,024 advanced UC tumors demonstrated some degree of HER2 protein expression detected using a standardized IHC method, whereas about 12% of specimens had ERBB2 gene amplification, including about 3% of those scored as either IHC 0 or 1+. Continued development of optimized and standardized HER2 testing methods is warranted to identify patients with HER2-expressing UC who may benefit from novel HER2-targeting therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
- Roche Diagnostics Solutions, Tucson, AZ.
- Pfizer Inc, Bothell, WA.
- Department of Pathology, Stanford University School of Medicine, Stanford, CA.
ORCID-Profile: Vadim S Koshkin, Johanna M Schafer, Naomi R M Schwartz, Emily Chan
Zitieren
APA
Koshkin, V. S., Schafer, J. M., Scherrer, E., Boyiddle, C., Schwartz, N. R. M., Yu, H., Fang, Q., Baker, A. F., Sayedian, F. H., & Chan, E. (2025). Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00879
Vancouver
Koshkin VS, Schafer JM, Scherrer E, Boyiddle C, Schwartz NRM, Yu H, et al. Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. JCO Precision Oncology. 2025. doi:10.1200/po-24-00879
BibTeX
@article{Koshkin2025,
author = {Koshkin, Vadim S and Schafer, Johanna M and Scherrer, Emilie and Boyiddle, Christine and Schwartz, Naomi R M and Yu, Hong and Fang, Qijun and Baker, Amanda F and Sayedian, Farzaneh H and Chan, Emily},
title = {Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-24-00879}
}
EUVIMED